JPMorgan analyst Cory Kasimov raised his price target for shares of bluebird bio to $150 ahead of additional pending updates for the company's novel gene therapy, LentiGlobin. Kasimov thinks data could be presented at this year's European Hematology Association, which begins on June 11. The analyst thinks early demonstration of proof-of-concept for LentiGlobin in Sickle Cell Disease could trigger "further material upside" in the stock. Kasimov recommends buying shares of bluebird into the data and keeps an Overweight rating on the name, calling the stock one of his top picks. The stock closed Friday up $1.58 to $133.93.